Numerous physiological samples are employed to find cancer biomarkers before the beginning of clinical signs. Different forms of cancer biomarkers may be retrieved from the tissue, blood, urine, or other body fluids, depending on the type of cancer. Over time and the discovery of new technology, numerous breakthroughs have been achieved in detecting these biomarkers. In addition to discovering biomarkers, new technologies have made it feasible to track these indicators throughout the therapy process following the completion of the treatment. Based on these results, the scientists concluded that when cancer starts, a specific and restricted number of biomarkers alter that, with the additional examination, lead to the discovery of specialized biomarkers for various forms of cancer. Specialists may utilize these capabilities to monitor cancer throughout the treatment and decide on some patient treatment plans. Immunotherapy is a treatment for several illnesses, including cancer, which promotes or inhibits the immune system response. Some interleukins, cytokines, and chemokines have been employed in this therapy. Immune system stimulation has been used to treat cancer and various immune system abnormalities. There are multiple approaches to treat cancer. Some of them improve the immune system in general. Others teach the immune system to target cancer cells selectively. Immunotherapy works better in certain forms of cancer than in others. Given this, it appears that the potential of monitoring the response to immunotherapy treatment using biomarkers is a novel way in the area of personalized medicine, and we may anticipate current successes in this field in the not too distant future.